Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{2583717eca794660be11a66bcc7e455c,
title = "Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors",
abstract = "Objectives: A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation.Methods: One-hundred-and-forty-three patients (91{\%} receiving TNF inhibitor and 9{\%} a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level.Results: One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 patients (62{\%}) had successfully tapered bDMARDs, with 26 (18{\%}) receiving two-thirds of standard dose, 39 (28{\%}) half dose and 22 (16{\%}) having discontinued; and 54 patients (38{\%}) were receiving full dose. ΔDAS28-CRP0-2yrs was 0.1((-0.2)-0.4) (median (interquartile range)) and mean ΔTotal-Sharp-Score0-2yrs was 0.01(1.15)(mean(s.d.)). Radiographic progression was observed in nine patients (7{\%}). Successful tapering was independently predicted by: ⩽1 previous bDMARD, male gender, low baseline MRI combined inflammation score or combined damage score. Negative IgM-RF predicted successful discontinuation.Conclusion: By implementing a clinical guideline, 62{\%} of RA patients in sustained remission in routine care were successfully tapered, including 16{\%} successfully discontinued at 2 years. Radiographic progression was rare. Maximum one bDMARDs, male gender, and low baseline MRI combined inflammation and combined damage scores were independent predictors for successful tapering.",
author = "Brahe, {Cecilie Heegaard} and Simon Krabbe and Mikkel {\O}stergaard and Lykke {\O}rnbjerg and Daniel Glinatsi and Henrik R{\o}gind and Jensen, {Hanne S} and Annette Hansen and Jesper N{\o}rregaard and S{\o}ren Jacobsen and Lene Terslev and Huynh, {Tuan K} and Jensen, {Dorte V} and Natalia Manilo and Karsten Asmussen and {Brown Frandsen}, Per and Mikael Boesen and Zoreh Rastiemadabadi and {Morsel Carlsen}, Lone and M{\o}ller, {Jakob M} and Krogh, {Niels S} and Hetland, {Merete Lund}",
note = "COPECARE",
year = "2019",
doi = "10.1093/rheumatology/key244",
language = "English",
volume = "58",
pages = "110--119",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - ABST

T1 - Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

AU - Brahe, Cecilie Heegaard

AU - Krabbe, Simon

AU - Østergaard, Mikkel

AU - Ørnbjerg, Lykke

AU - Glinatsi, Daniel

AU - Røgind, Henrik

AU - Jensen, Hanne S

AU - Hansen, Annette

AU - Nørregaard, Jesper

AU - Jacobsen, Søren

AU - Terslev, Lene

AU - Huynh, Tuan K

AU - Jensen, Dorte V

AU - Manilo, Natalia

AU - Asmussen, Karsten

AU - Brown Frandsen, Per

AU - Boesen, Mikael

AU - Rastiemadabadi, Zoreh

AU - Morsel Carlsen, Lone

AU - Møller, Jakob M

AU - Krogh, Niels S

AU - Hetland, Merete Lund

N1 - COPECARE

PY - 2019

Y1 - 2019

N2 - Objectives: A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation.Methods: One-hundred-and-forty-three patients (91% receiving TNF inhibitor and 9% a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level.Results: One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 patients (62%) had successfully tapered bDMARDs, with 26 (18%) receiving two-thirds of standard dose, 39 (28%) half dose and 22 (16%) having discontinued; and 54 patients (38%) were receiving full dose. ΔDAS28-CRP0-2yrs was 0.1((-0.2)-0.4) (median (interquartile range)) and mean ΔTotal-Sharp-Score0-2yrs was 0.01(1.15)(mean(s.d.)). Radiographic progression was observed in nine patients (7%). Successful tapering was independently predicted by: ⩽1 previous bDMARD, male gender, low baseline MRI combined inflammation score or combined damage score. Negative IgM-RF predicted successful discontinuation.Conclusion: By implementing a clinical guideline, 62% of RA patients in sustained remission in routine care were successfully tapered, including 16% successfully discontinued at 2 years. Radiographic progression was rare. Maximum one bDMARDs, male gender, and low baseline MRI combined inflammation and combined damage scores were independent predictors for successful tapering.

AB - Objectives: A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation.Methods: One-hundred-and-forty-three patients (91% receiving TNF inhibitor and 9% a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level.Results: One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 patients (62%) had successfully tapered bDMARDs, with 26 (18%) receiving two-thirds of standard dose, 39 (28%) half dose and 22 (16%) having discontinued; and 54 patients (38%) were receiving full dose. ΔDAS28-CRP0-2yrs was 0.1((-0.2)-0.4) (median (interquartile range)) and mean ΔTotal-Sharp-Score0-2yrs was 0.01(1.15)(mean(s.d.)). Radiographic progression was observed in nine patients (7%). Successful tapering was independently predicted by: ⩽1 previous bDMARD, male gender, low baseline MRI combined inflammation score or combined damage score. Negative IgM-RF predicted successful discontinuation.Conclusion: By implementing a clinical guideline, 62% of RA patients in sustained remission in routine care were successfully tapered, including 16% successfully discontinued at 2 years. Radiographic progression was rare. Maximum one bDMARDs, male gender, and low baseline MRI combined inflammation and combined damage scores were independent predictors for successful tapering.

U2 - 10.1093/rheumatology/key244

DO - 10.1093/rheumatology/key244

M3 - Conference abstract in journal

VL - 58

SP - 110

EP - 119

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 1

ER -

ID: 55215264